Viela Bio

Investors/Media

Press Releases

Press Releases

6.11.2020
Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
UPLIZNA™ is the first and only B cell depleter approved for the treatment of NMOSD in adults who are anti-aquaporin-4 (AQP4) antibody positive GAITHERSBURG, Md. , June 11, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE) today announced that the U.S. Food and Drug Administration (FDA) has approved
5.27.2020
Viela Bio Announces Pricing of Public Offering of Common Stock
GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq: VIE ), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at
5.27.2020
Viela Bio Announces Pricing of Public Offering of Common Stock
GAITHERSBURG, Md. , May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at
5.26.2020
Viela Bio Announces Proposed Public Offering of Common Stock
GAITHERSBURG, Md. , May 26, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced that it intends to offer and sell, subject to market and other conditions, 3,000,000
5.13.2020
Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights
Company to host investor conference call and webcast today at 5:00 pm ET GAITHERSBURG, Md. , May 13, 2020 (GLOBE NEWSWIRE) -- Viela Bio  (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today reported financial results and
5.13.2020
Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus
-Safety profile comparable to placebo control- -Potent depletion of plasmacytoid dendritic cells in peripheral blood and skin biopsies- -Dose-dependent improvements in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scores- GAITHERSBURG, Md.
5.06.2020
Viela Bio to Webcast First Quarter 2020 Financial Results and Program Highlights on May 13, 2020
GAITHERSBURG, Md. , May 06, 2020 (GLOBE NEWSWIRE) -- Viela Bio  (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today announced it will host a webcast and conference call on Wednesday, May 13, 2020 at 5:00 p.m.
4.30.2020
Viela Bio Announces Election of Rachelle Jacques to its Board of Directors
GAITHERSBURG, Md. , April 30, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the election of Rachelle Jacques to its Board of Directors.
3.25.2020
Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
Company to host investor conference call and webcast today at 5:00 pm ET GAITHERSBURG, Md. , March 25, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today reported financial results and
3.18.2020
Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020
GAITHERSBURG, Md. , March 18, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today announced it will host a webcast and conference call on Wednesday, March 25, 2020 at 5:00 p.m.

Shareholder Tools